Insulet (NASDAQ:PODD) Price Target Raised to $400.00 at Jefferies Financial Group

Insulet (NASDAQ:PODD) had its price target hoisted by Jefferies Financial Group from $375.00 to $400.00 in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. Jefferies Financial Group currently has a buy rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada increased their price objective on shares of Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research note on Friday, October 10th. Canaccord Genuity Group upped their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. Barclays increased their target price on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Wells Fargo & Company boosted their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $368.80.

Insulet Stock Down 1.1%

Shares of NASDAQ:PODD traded down $3.58 during trading on Thursday, hitting $319.82. 677,166 shares of the company’s stock traded hands, compared to its average volume of 721,278. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet has a 52 week low of $230.05 and a 52 week high of $353.50. The company has a 50-day moving average price of $325.46 and a 200-day moving average price of $308.84. The company has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PODD. Norges Bank bought a new position in shares of Insulet during the second quarter valued at $324,689,000. Qube Research & Technologies Ltd acquired a new position in shares of Insulet in the 2nd quarter valued at about $131,439,000. American Century Companies Inc. boosted its holdings in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Insulet during the 1st quarter worth approximately $74,163,000. Finally, Worldquant Millennium Advisors LLC bought a new stake in Insulet in the second quarter valued at $80,082,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.